9 June 2017 - Cost regulators for the NHS in England and Wales have published draft guidelines barring adults with gout from routine access to Gruenenthal’s Zurampic-based therapy for treating hyperuricaemia.

The National Institute for Health and Care Excellence has published an appraisal consultation document turning down the drug’s use within its marketing authorisation, that is, for treating hyperuricaemia in patients whose serum uric acid is above the target level despite an adequate dose of a xanthine oxidase inhibitor (XOI) alone.

Evidence from two randomised controlled trials showed that a target serum uric acid level is reached in more people having Zurampic (lesinurad) plus the XOI allopurinol than in those taking the latter the drug alone.

Read Pharma Times article